Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →U.K. biotech Bicycle Therapeutics has signed a deal with Genentech to develop immuno-oncology therapies based on its bicyclic peptide platform. Bicycle will…
Roche's Genentech has tapped Bicycle Therapeutics for a 1.7 billion dollar immuno-oncology collaboration, marking the highest-profile validation yet for…
Bicycle Therapeutics provided a strategic update on its Genentech collaboration on its second-quarter 2023 earnings call, noting continued advancement of…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Genentech (Roche) and Bicycle Therapeutics entered an exclusive strategic collaboration to discover, develop and commercialize Bicycle-based immuno-oncology therapies. Bicycle received $30M upfront with eligibility for up to ~$1.7B in milestones across multiple programs plus tiered royalties. Genentech selected initial two targets with options on additional targets via $10M expansion fees.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Bicycle Therapeutics plc (this deal) | 2020 | $1.7B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2020 deals · Roche Holding AG deals · Oncology deals